{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:16:16Z","timestamp":1773872176348,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,5,30]],"date-time":"2008-05-30T00:00:00Z","timestamp":1212105600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The -1438A\/G polymorphism of the 5-HT<jats:sub>2A<\/jats:sub>gene has been found to be associated with clinical response to clozapine and other second generation antipsychotics. Testing the impact of this marker on response to first generation antipsychotics (which have a lower affinity for the 5-HT<jats:sub>2A<\/jats:sub>receptor) provides the opportunity to help disentangling the two different roles that this polymorphism might have. A psychopharmacogenetic role should be detected only for antipsychotics with high affinity to the 5-HT<jats:sub>2A<\/jats:sub>receptor (therefore to second generation antipsychotics). An alternative role would imply tagging a subgroup of patients responsive to any antipsychotic, whatever their affinity, meaning that the association is more depending on non pharmacological charaterictics, such as clinical specificities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A family-based sample of 100 Algerian patients with schizophrenia (according to DSM-IV criteria) and their 200 biological parents was recruited, in order to avoid stratification biases. Patients were all treated, or have been treated, by conventional antipsychotics (mainly haloperidol) for at least four weeks, at appropriate dosage. May and Dencker scale was used to distinguish responders and non responders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No allele of the -1438A\/G polymorphism of the 5-HT<jats:sub>2A<\/jats:sub>gene was transmitted in excess (50 transmitted for 38 untransmitted) in the whole sample of patients with schizophrenia (p = .90). In contrast, a significant excess of transmission of the G allele was observed (p = .02) in the subgroup of patients with good treatment response (17 transmitted for 6 untransmitted).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Using a TDT approach, we showed that the G allele of the -1438A\/G polymorphism of the gene coding for the 5-HT<jats:sub>2A<\/jats:sub>receptor was associated to schizophrenia with good response to conventional antipsychotics, although this conclusion is based on 88 informative patients only. Because previous data showed the same result with atypical antipsychotics, it can be concluded that the G allele tags a subgroup of schizophrenic patients with greater chance of improvement with antipsychotics of either type.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-244x-8-40","type":"journal-article","created":{"date-parts":[[2008,5,30]],"date-time":"2008-05-30T18:13:16Z","timestamp":1212171196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Excess of transmission of the G allele of the -1438A\/G polymorphism of the 5-HT2Areceptor gene in patients with schizophrenia responsive to antipsychotics"],"prefix":"10.1186","volume":"8","author":[{"given":"Dalila","family":"Benmessaoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Hamdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudette","family":"Boni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Ramoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Hamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Kacha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Gorwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,30]]},"reference":[{"issue":"2","key":"484_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/schbul\/17.2.325","volume":"17","author":"RJ Wyatt","year":"1991","unstructured":"Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991, 17 (2): 325-351.","journal-title":"Schizophr Bull"},{"key":"484_CR2","first-page":"81","volume":"28","author":"MH Chakos","year":"1992","unstructured":"Chakos MH, Mayerhoff DI, Loebel AD, Alvir JM, Lieberman JA: Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia. Psychopharmacol Bull. 1992, 28: 81-86.","journal-title":"Psychopharmacol Bull"},{"key":"484_CR3","first-page":"365","volume":"29","author":"BJ Kinon","year":"1993","unstructured":"Kinon BJ, Kane JM, Chakos M, Munne E: Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull. 1993, 29: 365-369.","journal-title":"Psychopharmacol Bull"},{"issue":"Suppl 9","key":"484_CR4","first-page":"5","volume":"57","author":"JA Lieberman","year":"1996","unstructured":"Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, Bilder R: Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996, 57 (Suppl 9): 5-9.","journal-title":"J Clin Psychiatry"},{"key":"484_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/0-387-34577-2_1","volume-title":"Psychopharmacogenetics","author":"P Gorwood","year":"2006","unstructured":"Gorwood P, Foot E: Introduction on psychopharmacogenetics. Psychopharmacogenetics. Edited by: Philip Gorwood, Michel Hamon. 2006, Springer Inc;, 1-24."},{"issue":"2","key":"484_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","volume":"25","author":"R Keefe","year":"1999","unstructured":"Keefe R, Silva SG, Perkins DO, Lieberman JA: The effects of antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull. 1999, 25 (2): 201-222.","journal-title":"Schizophr Bull"},{"key":"484_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/0888-7543(91)90411-7","volume":"9","author":"RS Sparkes","year":"1991","unstructured":"Sparkes RS, Lan N, Klisak I, Mohandas T, Diep A, Kojis T, Heinzmann C, Shih JC: Assignment of a serotonin 5-HT-2 receptor gene (HTR2) to human chromosome 13q14-q21 and mouse chromosome 14. Genomics. 1991, 9: 461-465.","journal-title":"Genomics"},{"key":"484_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0920-9964(03)00183-X","volume":"67","author":"HM Abdolmaleky","year":"2004","unstructured":"Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT: Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res. 2004, 67: 53-62.","journal-title":"Schizophr Res"},{"key":"484_CR9","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.biopsych.2006.06.024","volume":"60","author":"Y Fukuda","year":"2006","unstructured":"Fukuda Y, Koga M, Arai M, Noguchi E, Ohtsuki T, Horiuchi Y, Ishiguro H, Niizato K, Iritani S, Itokawa M, Arinami T: Monoallelic and unequal allelic expression of the HTR2A gene in human brain and peripheral lymphocytes. Biol Psychiatry. 2006, 60: 1331-1335.","journal-title":"Biol Psychiatry"},{"key":"484_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(95)92168-0","volume":"346","author":"MJ Arranz","year":"1995","unstructured":"Arranz MJ, Collier DA, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R: Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 1995, 346: 281-282.","journal-title":"Lancet"},{"key":"484_CR11","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1093\/hmg\/3.12.2207","volume":"3","author":"MM N\u00f6then","year":"1994","unstructured":"N\u00f6then MM, Cichon S, Hemmer S, Hebebrand J, Remschmidt H, Lehmkuhl G, Poustka F, Schmidt M, Catalano M, Fimmers R, K\u00f6mer J, Rletschel M, Propping P: Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Genet. 1994, 3: 2207-2212.","journal-title":"Hum Mol Genet"},{"key":"484_CR12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1176\/ajp.153.8.1092","volume":"153","author":"AK Malhorta","year":"1996","unstructured":"Malhorta AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D: Lack of association between polymorphisms in the 5-HT2A receptor and the antipsychotic response to clozapine. Am J Psychiatry. 1996, 153: 1092-1094.","journal-title":"Am J Psychiatry"},{"key":"484_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00041444-199621000-00005","volume":"6","author":"VL Nimgaonkar","year":"1996","unstructured":"Nimgaonkar VL, Zhang XR, Brar JS, DeLeo M, Ganguli R: 5-HT2A receptor gene locus: association with schizophrenia or treatment response not detected. Psy Genet. 1996, 6: 23-27.","journal-title":"Psy Genet"},{"key":"484_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0893-133X(98)00007-4","volume":"19","author":"M Masellis","year":"1998","unstructured":"Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, Cola P, Howard A, Badri F, N\u00f6then MM, Kalow W, Kennedy JL: Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 1998, 19: 123-132.","journal-title":"Neuropsychopharmacology"},{"key":"484_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00001756-199901180-00011","volume":"10","author":"CH Lin","year":"1999","unstructured":"Lin CH, Tsai SJ, Yu YWY, Song HL, Tu PC, Sim CB, Hsu CP, Yang KH, Hong CJ: No evidence for association of serotonin-2A receptor variant (102T\/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport. 1999, 10: 57-60.","journal-title":"Neuroreport"},{"key":"484_CR16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/S0140-6736(05)74176-3","volume":"356","author":"J Schumacher","year":"2000","unstructured":"Schumacher J, Schulze TG, Wienker TF, Rietschel M, N\u00f6then MM: Pharmacogenetics of the clozapine response. Lancet. 2000, 356: 506-","journal-title":"Lancet"},{"key":"484_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.mp.4000348","volume":"3","author":"MJ Arranz","year":"1998","unstructured":"Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J, Kirov G, Collier DA, Kerwin RW: Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry. 1998, 3: 61-66.","journal-title":"Mol Psychiatry"},{"key":"484_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0920-9964(98)00032-2","volume":"32","author":"MJ Arranz","year":"1998","unstructured":"Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA, Kerwin RW: Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res. 1998, 32: 93-99.","journal-title":"Schizophr Res"},{"key":"484_CR19","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1176\/appi.ajp.159.9.1593","volume":"159","author":"HY Lane","year":"2002","unstructured":"Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH: Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry. 2002, 159: 1593-1595.","journal-title":"Am J Psychiatry"},{"key":"484_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neulet.2004.11.070","volume":"377","author":"N Hamdani","year":"2005","unstructured":"Hamdani N, Bonniere M, Ades J, Hamon M, Boni C, Gorwood P: Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci Lett. 2005, 377: 69-74.","journal-title":"Neurosci Lett"},{"key":"484_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1086\/303007","volume":"67","author":"JC Whittaker","year":"2000","unstructured":"Whittaker JC, Denham MC, Morris AP: The problems of using the transmission\/disequilibrium test to infer tight linkage. Am J Hum Genet. 2000, 67: 523-526.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"484_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/schbul\/16.4.551","volume":"16","author":"HD Brenner","year":"1990","unstructured":"Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, Kulhanek F, Liberman RP, Malm U, Midha KK: Defining treatment refractoriness in schizophrenia. Schizophr Bull. 1990, 16 (4): 551-560.","journal-title":"Schizophr Bull"},{"key":"484_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/archpsyc.1994.03950110009002","volume":"51","author":"JI Nurnberger Jr","year":"1994","unstructured":"Nurnberger JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T: Arch Gen Psychiatry. 1994, 51: 849-859.","journal-title":"Arch Gen Psychiatry"},{"key":"484_CR24","volume-title":"Scale for assessment of negative symptoms (SANS)","author":"NC Andreasen","year":"1984","unstructured":"Andreasen NC: Scale for assessment of negative symptoms (SANS). 1984, University of Iowa, Iowa City"},{"issue":"suppl.44","key":"484_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"SG Simpson","year":"1970","unstructured":"Simpson SG, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970, 212 (suppl.44): 11-9.","journal-title":"Acta Psychiatr Scand"},{"key":"484_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/sj.ejhg.5200625","volume":"9","author":"S Horvath","year":"1998","unstructured":"Horvath S, Xu X, Laird NM: The family based association test method: strategies for studying general genotype-phenotype associations. Eur J Hum Genet. 1998, 9: 301-306.","journal-title":"Eur J Hum Genet"},{"key":"484_CR27","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1126\/science.273.5281.1516","volume":"273","author":"N Risch","year":"1996","unstructured":"Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science. 1996, 273: 1516-1517.","journal-title":"Science"},{"key":"484_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1086\/381563","volume":"74","author":"C Lange","year":"2004","unstructured":"Lange C, DeMeo D, Silverman EK, Weiss ST, Laird NM: PBAT: tools for family-based association studies. Am J Hum Genet. 2004, 74: 367-369.","journal-title":"Am J Hum Genet"},{"key":"484_CR29","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"S Miller","year":"1988","unstructured":"Miller S, Dykes D, Polesky H: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16: 1215-","journal-title":"Nucleic Acids Res"},{"key":"484_CR30","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0140-6736(95)91590-7","volume":"346","author":"B Gutierrez","year":"1995","unstructured":"Gutierrez B, Arranz M., Fananas L, Vall\u00e8s V, Guillamat R, van Os J, Collier D: 5-HT2A receptor gene and bipolar affective disorder. Lancet. 1995, 346: 969-","journal-title":"Lancet"},{"key":"484_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.eurpsy.2006.06.002","volume":"22","author":"VE Golimbet","year":"2007","unstructured":"Golimbet VE, Lavrushina OM, Kaleda VG, Abramova LI, Lezheiko TV: Supportive evidence for the association between the T102C 5-HTR2A gene polymorphism and schizophrenia: a large-scale case-control and family-based study. Eur Psychiatry. 2007, 22: 167-170.","journal-title":"Eur Psychiatry"},{"key":"484_CR32","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/jnr.10173","volume":"67","author":"OO Polesskaya","year":"2002","unstructured":"Polesskaya OO, Sokolov BP: Differential expression of the \"C\" and \"T\" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res. 2002, 67: 812-822.","journal-title":"J Neurosci Res"},{"key":"484_CR33","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1176\/ajp.156.9.1456","volume":"156","author":"G Turecki","year":"1999","unstructured":"Turecki G, Briere R, Dewar K, Antonetti T, Lesage AD, Seguin M, Chawky N, Vanier C, Alda M, Joober R, Benkelfat C, Rouleau GA: Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry. 1999, 156: 1456-1458.","journal-title":"Am J Psychiatry"},{"key":"484_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.mp.4000842","volume":"6","author":"RH Segman","year":"2001","unstructured":"Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, Dorevitch A, Yakir A, Greenberg D, Lerner A, Lerer B: Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry. 2001, 6: 225-229.","journal-title":"Mol Psychiatry"},{"key":"484_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1017\/S1092852900020903","volume":"12","author":"DJ Stein","year":"2007","unstructured":"Stein DJ, Hemmings S, Moolman-Smook H, Audenaert K: 5-HT2A: its role in frontally mediated executive function and related psychopathology. CNS Spectr. 2007, 12: 512-516.","journal-title":"CNS Spectr"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-8-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-8-40\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-8-40","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-8-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T22:45:35Z","timestamp":1708987535000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-8-40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,30]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-8-40","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,30]]},"assertion":[{"value":"24 September 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"40"}}